Sure, it's still cold across most of the country. After all, the famous groundhog in Punxsutawney, Pa., did see his shadow in early February. According to the legend, that means we still have a few more weeks of winter. However, some health-care stocks are already generating so much heat you'd think it was summer.
One of these sizzling stocks announced terrific late-stage clinical results for a lead drug. Another scored an options licensing deal with a major pharmaceutical company. Our third big winner of the week benefited from a price target upgrade.
Which stocks made this week's most humongous list? Find out by watching the following slideshow.
Keith Speights and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.